Evaluation of Autoimmune FVIII Inhibitor Using Clot Waveform Analysis in Emicizumab-Treated Patients
Shigehisa Tamaki, Hideo Wada, Naoki Shinke, Junichiro Nishiki, Ryota Sasao, Atsushi Fujieda, Takeshi Matsumoto, Isao Tawara, Teruto Hashiguchi · 2025
Read Evaluation of Autoimmune FVIII Inhibitor Using Clot Waveform Analysis in Emicizumab-Treated Patients by Shigehisa Tamaki, Hideo Wada, Naoki Shinke, Junichiro Nishiki, Ryota Sasao, Atsushi Fujieda, Takeshi Matsumoto, Isao Tawara, Teruto Hashiguchi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12787131.txt.
Description
Shigehisa Tamaki and co-authors test a waveform method for tracking a rare bleeding disorder in patients on a new antibody drug, in a 2025 study. In this disorder, the immune system attacks factor VIII, a protein blood needs to clot. The drug emicizumab treats it well, but it distorts the standard clotting tests doctors rely on. The team used clot waveform analysis, which reads the shape of the clotting curve.
Across three cases, one waveform variant tracked the factor VIII activity left in the blood. The team also found that common test reagents differ in how sensitive they are to the disorder. The drug stopped major bleeding in the cases studied. Antibody levels against factor VIII could still be measured during treatment with the waveform method. The authors offer it as a practical monitoring tool.
Catalog record
| CREATOR | Shigehisa Tamaki, Hideo Wada, Naoki Shinke, Junichiro Nishiki, Ryota Sasao, Atsushi Fujieda, Takeshi Matsumoto, Isao Tawara, Teruto Hashiguchi |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |